Natco Pharma Limited (NATCOPHARM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Natco Pharma Limited (NATCOPHARM) has a cash flow conversion efficiency ratio of 0.138x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs11.91 Billion ≈ $128.76 Million USD) by net assets (Rs86.54 Billion ≈ $935.92 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Natco Pharma Limited - Cash Flow Conversion Efficiency Trend (2005–2025)
This chart illustrates how Natco Pharma Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read debt load of Natco Pharma Limited for a breakdown of total debt and financial obligations.
Natco Pharma Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Natco Pharma Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Theon International Plc
AS:THEON
|
-0.012x |
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
|
0.237x |
|
Chongqing Fuling Zhacai Group Co Ltd
SHE:002507
|
0.042x |
|
Eternal Asia Supply Chain Management Ltd
SHE:002183
|
-0.011x |
|
The Baldwin Insurance Group, Inc.
NASDAQ:BWIN
|
0.009x |
|
Freehold Royalties Ltd.
TO:FRU
|
0.058x |
|
IJM Corporation Bhd
KLSE:3336
|
0.010x |
|
Wuxi Best Precision Machinery Co Ltd
SHE:300580
|
0.036x |
Annual Cash Flow Conversion Efficiency for Natco Pharma Limited (2005–2025)
The table below shows the annual cash flow conversion efficiency of Natco Pharma Limited from 2005 to 2025. For the full company profile with market capitalisation and key ratios, see NATCOPHARM market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | Rs76.12 Billion ≈ $823.24 Million |
Rs16.97 Billion ≈ $183.50 Million |
0.223x | +4.18% |
| 2024-03-31 | Rs58.53 Billion ≈ $632.99 Million |
Rs12.52 Billion ≈ $135.43 Million |
0.214x | +130.24% |
| 2023-03-31 | Rs91.37 Billion ≈ $988.18 Million |
Rs8.49 Billion ≈ $91.83 Million |
0.093x | +752.04% |
| 2022-03-31 | Rs42.64 Billion ≈ $461.09 Million |
Rs465.00 Million ≈ $5.03 Million |
0.011x | -84.95% |
| 2021-03-31 | Rs41.23 Billion ≈ $445.93 Million |
Rs2.99 Billion ≈ $32.31 Million |
0.072x | -34.28% |
| 2020-03-31 | Rs37.85 Billion ≈ $409.30 Million |
Rs4.17 Billion ≈ $45.13 Million |
0.110x | -42.45% |
| 2019-03-31 | Rs34.91 Billion ≈ $377.54 Million |
Rs6.69 Billion ≈ $72.33 Million |
0.192x | +27.11% |
| 2018-03-31 | Rs30.76 Billion ≈ $332.66 Million |
Rs4.64 Billion ≈ $50.14 Million |
0.151x | -27.94% |
| 2017-03-31 | Rs16.53 Billion ≈ $178.81 Million |
Rs3.46 Billion ≈ $37.40 Million |
0.209x | +166.23% |
| 2016-03-31 | Rs13.03 Billion ≈ $140.94 Million |
Rs1.02 Billion ≈ $11.07 Million |
0.079x | -27.85% |
| 2015-03-31 | Rs8.51 Billion ≈ $92.04 Million |
Rs926.66 Million ≈ $10.02 Million |
0.109x | -44.61% |
| 2014-03-31 | Rs7.33 Billion ≈ $79.24 Million |
Rs1.44 Billion ≈ $15.58 Million |
0.197x | +74.77% |
| 2013-03-31 | Rs5.44 Billion ≈ $58.84 Million |
Rs611.95 Million ≈ $6.62 Million |
0.112x | -18.24% |
| 2012-03-31 | Rs4.72 Billion ≈ $51.05 Million |
Rs649.41 Million ≈ $7.02 Million |
0.138x | -28.06% |
| 2011-03-31 | Rs3.53 Billion ≈ $38.23 Million |
Rs675.97 Million ≈ $7.31 Million |
0.191x | -23.21% |
| 2010-03-31 | Rs3.11 Billion ≈ $33.60 Million |
Rs773.69 Million ≈ $8.37 Million |
0.249x | +77.24% |
| 2009-03-31 | Rs2.66 Billion ≈ $28.77 Million |
Rs373.85 Million ≈ $4.04 Million |
0.141x | -34.64% |
| 2008-03-31 | Rs2.25 Billion ≈ $24.34 Million |
Rs483.90 Million ≈ $5.23 Million |
0.215x | -11.13% |
| 2007-03-31 | Rs1.86 Billion ≈ $20.12 Million |
Rs450.03 Million ≈ $4.87 Million |
0.242x | +19.35% |
| 2006-03-31 | Rs1.54 Billion ≈ $16.64 Million |
Rs311.81 Million ≈ $3.37 Million |
0.203x | -52.96% |
| 2005-03-31 | Rs1.14 Billion ≈ $12.29 Million |
Rs489.69 Million ≈ $5.30 Million |
0.431x | -- |
About Natco Pharma Limited
NATCO Pharma Limited, a pharmaceutical company, engages in the research and development, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. The company offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; a… Read more